BioSpace News Archive

Outlook Therapeutics, Inc. today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in the H.C. Wainwright Ophthalmology Virtual Conference being held Tuesday, August 17, 2021 from 9:00 – 10:00 a.m. ET .

The first cohort has completed dosing with IN8bio’s donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) observed to date

Summit Therapeutics Inc. today reports its financial results and provides an update on its operational progress for the second quarter and six months ended June 30, 2021.

Lumen Bioscience, a clinical-stage biopharmaceutical company developing products to treat and prevent highly prevalent diseases, today announced the results of a research collaboration with Google that applied machine learning (ML) to significantly advance the scalability of spirulina-based biologic drugs.

Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the results of a new real-world study that shows its ECHELON CIRCULAR Powered Stapler was associated with a 74% reduction in anastomotic leak rates (1.8% vs. 6.9%)1 and a 44% reduction in 30-day inpatient hospital readmission rates (6.1% vs.10.8%) after colorectal surgery compared with manual circular staplers

Cyanotech Corporation announced financial results for the first quarter of fiscal year 2022, ended June 30, 2021.

3NT Medical today announced FDA clearance for its Peregrine™ Drivable ENT Scope, designed to provide ENT surgeons with unparalleled views of the sinus anatomy to enhance the surgical experience.

Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has issued a notice of allowance for Biomerica’s first patent pertaining to a revolutionary new treatment option for patients suffering from depression.

Predictive Oncology announced today that the Company’s Special Meeting of Stockholders, which was convened at 3:00 p.m. Central Time on August 10, 2021, has been adjourned for the purpose of soliciting more votes on the proposal to approve an amendment to the Company’s certificate of incorporation

Dyadic today announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic’s lead COVID-19 vaccine candidate, DYAI-100.